Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles European Thyroid Journal Year : 2021

Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib

Abstract

Background: Cardiac metastases from thyroid cancers are uncommon with a poor prognosis. There is a lack of long-term follow-up studies. Cases: We report 2 cases of cardiac metastasis from medullary thyroid cancer (MTC). Both patients presented limited metastatic disease apart from a cardiac metastasis. The initial diagnosis was challenging and was facilitated by functional imaging with an immuno-PET-CT using an anti-CEA bispecific antibody and a 68Ga-labeled peptide. Both patients were treated with the multitarget kinase inhibitor vandetanib with prolonged stability. The first patient was alive at the last follow-up, 14 years after the diagnosis of cardiac metastasis. The second patient required surgical excision of the cardiac mass because of disease progression under vandetanib. Conclusion: These cases illustrate long-term survival and effectiveness of clinical management of 2 patients who developed cardiac metastases from MTC, in the current era of personalized medicine with targeted therapy.
Fichier principal
Vignette du fichier
[22350802 - European Thyroid Journal] Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib.pdf (466.29 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03547147 , version 1 (28-01-2022)

Identifiers

Cite

Camille Buffet, Sophie Leboulleux, Françoise Kraeber-Bodéré, Caroline Bodet-Milin, Laure Cabanes, et al.. Cardiac Metastasis from Medullary Thyroid Cancers with Long-Term Survival under Vandetanib. European Thyroid Journal , 2021, 10 (6), pp.517-522. ⟨10.1159/000517716⟩. ⟨inserm-03547147⟩
32 View
35 Download

Altmetric

Share

Gmail Facebook X LinkedIn More